| Full Name | Thang Quoc Le |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 325 9th Ave, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013277821 | NPI | - | NPPES |
| 1013277821 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD60934917 (Washington) | Secondary |
| 2085R0204X | Radiology - Vascular & Interventional Radiology | MD60934917 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Garfield Medical Center | Monterey park, CA | Hospital |
| Southern California Hospital At Hollywood | Hollywood, CA | Hospital |
| Ahmc Anaheim Regional Medical Center | Anaheim, CA | Hospital |
| Los Angeles Community Hospital | Los angeles, CA | Hospital |
| Alhambra Hospital Medical Center | Alhambra, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kc Tan, M.d. Medical Corporation | 2062719719 | 40 |
News Archive
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Noting "April 25 marks World Malaria Day, an opportunity for those who work to defeat the illness to review progress and renew commitments," Laurence Slutsker and Patrick Kachur of the CDC's Division of Parasitic Diseases and Malaria, write in a Malaria Journal opinion piece, "After a decade of steady success, this year's commemoration of the date is also an opportunity to reconsider current approaches and assess the state of the science needed to keep pace in the global effort to combat malaria."
› Verified 4 days ago
| Entity Name | Hanford Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538141627 PECOS PAC ID: 7416868377 Enrollment ID: O20040325000272 |
News Archive
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Noting "April 25 marks World Malaria Day, an opportunity for those who work to defeat the illness to review progress and renew commitments," Laurence Slutsker and Patrick Kachur of the CDC's Division of Parasitic Diseases and Malaria, write in a Malaria Journal opinion piece, "After a decade of steady success, this year's commemoration of the date is also an opportunity to reconsider current approaches and assess the state of the science needed to keep pace in the global effort to combat malaria."
› Verified 4 days ago
| Entity Name | Kc Tan, M.d. Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215394036 PECOS PAC ID: 2062719719 Enrollment ID: O20160324000980 |
News Archive
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Noting "April 25 marks World Malaria Day, an opportunity for those who work to defeat the illness to review progress and renew commitments," Laurence Slutsker and Patrick Kachur of the CDC's Division of Parasitic Diseases and Malaria, write in a Malaria Journal opinion piece, "After a decade of steady success, this year's commemoration of the date is also an opportunity to reconsider current approaches and assess the state of the science needed to keep pace in the global effort to combat malaria."
› Verified 4 days ago
| Entity Name | Reedley Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336167550 PECOS PAC ID: 0941460984 Enrollment ID: O20201224000078 |
News Archive
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Noting "April 25 marks World Malaria Day, an opportunity for those who work to defeat the illness to review progress and renew commitments," Laurence Slutsker and Patrick Kachur of the CDC's Division of Parasitic Diseases and Malaria, write in a Malaria Journal opinion piece, "After a decade of steady success, this year's commemoration of the date is also an opportunity to reconsider current approaches and assess the state of the science needed to keep pace in the global effort to combat malaria."
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thang Quoc Le, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | Thang Quoc Le, MD 325 9th Ave, Seattle, WA 98104 Ph: (206) 520-5000 |
News Archive
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Noting "April 25 marks World Malaria Day, an opportunity for those who work to defeat the illness to review progress and renew commitments," Laurence Slutsker and Patrick Kachur of the CDC's Division of Parasitic Diseases and Malaria, write in a Malaria Journal opinion piece, "After a decade of steady success, this year's commemoration of the date is also an opportunity to reconsider current approaches and assess the state of the science needed to keep pace in the global effort to combat malaria."
› Verified 4 days ago
Laura Morrison, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 904 7th Ave, Seattle, WA 98104 Phone: 206-860-4691 Fax: 206-329-1261 | |
Dr. Sarah Bastawrous, DO Radiology Medicare: Not Enrolled in Medicare Practice Location: 1660 S Columbian Way, Diagnostic Imaging, S-rad-114, Seattle, WA 98108 Phone: 312-450-5258 | |
Bahar Mansoori, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-520-5000 | |
Dr. Guilherme Moura Da Cunha, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-520-5000 | |
Richard Ha, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, C-212, Box 356340, Seattle, WA 98195 Phone: 206-543-0065 | |
Patrick C Freeny, Radiology Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-598-6214 | |
Dr. Julie Emiko Takasugi, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1660 S Columbian Way, Dept. Radiology S-113, Psvahcs, Seattle, WA 98108 Phone: 206-764-2444 Fax: 206-277-3415 |